Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04622709

Enrollment

Registered

2020-11-10

Start date

2020-10-07

Completion date

2021-06-22

Last updated

2022-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Requiring Chronic Dialysis

Keywords

Hemodialysis, Dialysis, End Stage Renal Disease, Patient-reported Outcomes, Symptoms, Diuretic, Furosemide, Lasix

Brief summary

Individuals with kidney failure receiving maintenance hemodialysis (HD) have high mortality rates, driven largely by cardiovascular causes. Volume-related factors are critical, modifiable contributors to cardiovascular complications. Reversing volume overload has been shown to improve blood pressure and cardiac remodeling. Use of loop diuretics may represent a pragmatic, low-cost, and low-burden strategy to improve outcomes in people receiving HD. Lack of data on optimal furosemide dosing, safety, and acceptability are barriers to expanded use. This study investigates whether oral furosemide is safe and effective at increasing urine volume in HD patients.

Interventions

DRUGFurosemide (loop diuretic) Tablets

Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

This is a single-center (multi-clinic), open-label, non-randomized pilot study to test whether oral furosemide is safe and effective at increasing urine volume in HD patients. The study will consist of 2 periods: a 6-week dose escalation period (period 1) and a subsequent 12-week follow-up period (period 2). During period 1, all participants will receive escalating doses of furosemide as tolerated, and the short-term safety, tolerability, and efficacy of furosemide will be examined. During period 2, all participants will continue the maximally tolerated period 1 furosemide dose, and the acceptability of and adherence to furosemide and the longer-term safety and efficacy of furosemide will be examined.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient self-report of at least 1 cup urine/24-hours * Age ≥18 years * Receipt of thrice weekly in-center HD at a participating clinic (UNC-associated Carolina Dialysis- Carrboro, Siler City, Pittsboro, Sanford, and Lee County) * ≥60 days receiving in-center HD * Willingness to take study medication and undergo study testing * Ability to provide informed consent

Exclusion criteria

* Known allergy to loop diuretic * History of poor adherence to HD or medical regimen per nephrologist * \>1 hospitalization in prior 30-days * Frequent hypotension (systolic BP \<80 mmHg at \>30% of HD treatments in prior 30-days) * Cirrhosis per nephrologist * Hearing disorder per nephrologist * Serum potassium \<3.5 mEq/L, magnesium \<1 mg/dL, or corrected calcium \<8 mg/dL in prior 30-days * Taking a non-loop diuretic (e.g. spironolactone, eplerenone, ethacrynic acid, thiazides) * Taking an aminoglycoside, cisplatin, methotrexate, cyclosporine, adrenocorticotropic hormone (ACTH), lithium, phenytoin, or oral/intravenous steroid * Natural licorice consumption * Prisoners, patients with significant mental illness * Pregnant patients and nursing mothers

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 5	Baseline and study week 5 (5 weeks after study medication start	Participants will follow standard dialysis clinic protocols for 24-urine volume collection. Classifying participants as has having an increase in 24-hour urine volume will be contingent on the amount of urine the participant makes at baseline. * Among participants with baseline 24-hour urine volume ≥200 mL: ≥25% increase in urine volume is considered an increase. * Among participants with baseline 24-hour urine volume \<200 mL: ≥50 mL increase in urine volume to a urine volume of at least 100 mL/24-hours is considered an increase. The percentage of participants who have a defined increase in 24-urine volume from baseline to week 5 will be determined.
Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 12	Baseline and study week 12 (12 weeks after study medication start)	Participants will follow standard dialysis clinic protocols for 24-urine volume collection. Classifying participants as has having an increase in 24-hour urine volume will be contingent on the amount of urine the participant makes at baseline. * Among participants with baseline 24-hour urine volume ≥200 mL: ≥25% increase in urine volume is considered an increase. * Among participants with baseline 24-hour urine volume \<200 mL: ≥50 mL increase in urine volume to a urine volume of at least 100 mL/24-hours is considered an increase. The percentage of participants who have a defined increase in 24-urine volume from baseline to week 12 will be determined.
Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 18	Baseline and study week 18 (18 weeks after study medication start)	Participants will follow standard dialysis clinic protocols for 24-urine volume collection. Classifying participants as has having an increase in 24-hour urine volume will be contingent on the amount of urine the participant makes at baseline. * Among participants with baseline 24-hour urine volume ≥200 mL: ≥25% increase in urine volume is considered an increase. * Among participants with baseline 24-hour urine volume \<200 mL: ≥50 mL increase in urine volume to a urine volume of at least 100 mL/24-hours is considered an increase. The percentage of participants who have a defined increase in 24-urine volume from baseline to week 18 will be determined.
Percentage of Participants With A Serum Potassium <3.2 mEq/L at Week 1	Study week 1 (1 week after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 2	Study week 2 (2 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 3	Study week 3 (3 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 4	Study week 4 (4 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 5	Study week 5 (5 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 6	Study week 6 (6 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 9	Study week 9 (9 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 13	Study week 13 (13 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 17	Study week 17 (17 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 1	Study week 1 (1 week after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 2	Study week 2 (2 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 3	Study week 3 (3 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 4	Study week 4 (4 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 5	Study week 5 (5 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 6	Study week 6 (6 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 9	Study week 9 (9 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 13	Study week 13 (13 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 17	Study week 17 (17 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 1	Study week 1 (1 week after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 2	Study week 2 (2 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 3	Study week 3 (3 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 4	Study week 4 (4 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 5	Study week 5 (5 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 6	Study week 6 (6 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 9	Study week 9 (9 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 13	Study week 13 (13 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 17	Study week 17 (17 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 1.	Study week 1 (1 week after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 2.	Study week 2 (2 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 3.	Study week 3 (3 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 4.	Study week 4 (4 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 5.	Study week 5 (5 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 6.	Study week 6 (6 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 9.	Study week 9 (9 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 13.	Study week 13 (13 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 17.	Study week 17 (17 weeks after study medication start)	Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 1	Up to study week 1 (1 week after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 1 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 2	Up to study week 2 (2 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 2 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 3	Up to study week 3 (3 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 3 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 4	Up to study week 4 (4 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 4 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 5	Up to study week 5 (5 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 5 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 6	Up to study week 6 (6 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 6 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 7	Up to study week 7 (7 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 7 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 8	Up to study week 8 (8 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 8 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 9	Up to study week 9 (9 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 9 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 10	Up to study week 10 (10 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 10 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 11	Up to study week 11 (11 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 11 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 12	Up to study week 12 (12 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 12 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 13	Up to study week 13 (13 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 13 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 14	Up to study week 14 (14 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 14 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 15	Up to study week 15 (15 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 15 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 16	Up to study week 16 (16 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 16 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 17	Up to study week 17 (17 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 17 will be determined.
Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 18	Up to study week 18 (18 weeks after study medication start)	Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 18 will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 1	Baseline and study week 1 (1 week after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 1. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 2	Baseline and study week 2 (2 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 2. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 3	Baseline and study week 3 (3 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 3. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 4	Baseline and study week 4 (4 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 4. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 5	Baseline and study week 5 (5 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 5. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 6	Baseline and study week 6 (6 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 6. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 8	Baseline and study week 8 (8 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 8. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 10	Baseline and study week 10 (10 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 10. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 12	Baseline and study week 12 (12 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 12. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 14	Baseline and study week 14 (14 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 14. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Change in the Inner EAR Instrument Score From Baseline to Week 16	Baseline and study week 16 (16 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 16. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.
Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 18	Baseline and study week 18 (18 weeks after study medication start)	Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 18. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 3	Study week 3 (3 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 3. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 1	Study week 1 (1 week after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 1. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 2	Study week 2 (2 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 2. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 3	Study week 3 (3 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 3. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 4	Study week 4 (4 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 4. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 5	Study week 5 (5 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 5. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 6	Study week 6 (6 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 6. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 8	Study week 8 (8 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 8. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 10	Study week 10 (10 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 10. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 12	Study week 12 (12 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 12. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 14	Study week 14 (14 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 14. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 16	Study week 16 (16 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 16. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Reporting Acceptance of Furosemide at Week 18	Study week 18 (18 weeks after study medication start)	Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 18. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 1	Study week 1 (1 week after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 1. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 2	Study week 2 (2 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 2. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 4	Study week 4 (4 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 4. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 5	Study week 5 (5 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 5. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 6	Study week 6 (6 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 6. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 8	Study week 8 (8 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 8. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 10	Study week 10 (10 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 10. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 12	Study week 12 (12 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 12. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 14	Study week 14 (14 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 14. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 16	Study week 16 (16 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 16. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 18	Study week 18 (18 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 18. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.
Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 19	Study week 19 (19 weeks after study medication start)	Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 19. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Study Drug Administration: Furosemide Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant. Furosemide (loop diuretic) Tablets: Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.	39
Total	39

Arm

Count

Study Drug Administration: Furosemide

Study participants will receive furosemide oral tablets to be taken twice daily. During study period 1 (first 6 weeks), the drug dose will be escalated every 2 weeks if safe, tolerated, and acceptable to the participant. During study period 2 (subsequent 12 weeks), participants will take the maximum tolerated dose from study period 1, received every 4 weeks if safe, tolerated, and acceptable to the participant. Furosemide (loop diuretic) Tablets: Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd & 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.

Total

Baseline characteristics

Characteristic	Study Drug Administration: Furosemide
Age, Continuous	65 years
Ethnicity (NIH/OMB) Hispanic or Latino	6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	33 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	0 Participants
Race (NIH/OMB) Black or African American	23 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants
Race (NIH/OMB) White	14 Participants
Region of Enrollment United States	39 Participants
Sex: Female, Male Female	10 Participants
Sex: Female, Male Male	29 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	2 / 39
other Total, other adverse events	6 / 39
serious Total, serious adverse events	8 / 39

Outcome results

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 1

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 1. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 1 (1 week after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 12

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 12. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 12 (12 weeks after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 16

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 16. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 16 (16 weeks after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 3

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 3. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 3 (3 weeks after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 5

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 5. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 5 (5 weeks after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Change in the Inner EAR Instrument Score From Baseline to Week 8

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 8. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score.

Time frame: Baseline and study week 8 (8 weeks after study medication start)

Population: This outcome was entered in error. Data was not collected on this outcome, per the study protocol.

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 1

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 1. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 38 participants completed the week 1 acceptance assessment. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 1	97 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 10

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 10. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 28 participants completed the week 10 acceptance assessment. Thus, the analysis population is 28 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 10	89 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 12

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 12. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 26 participants completed the week 12 acceptance assessment. Thus, the analysis population is 26 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 12	96 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 14

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 14. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 26 participants completed the week 14 acceptance assessment. Thus, the analysis population is 26 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 14	96 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 16

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 16. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 26 participants completed the week 16 acceptance assessment. Thus, the analysis population is 26 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 16	96 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 18

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 18. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 25 participants completed the week 18 acceptance assessment. Thus, the analysis population is 25 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 18	92 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 2

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 2. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 35 participants completed the week 2 acceptance assessment. Thus, the analysis population is 35 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 2	97 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 3

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 3. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 35 participants completed the week 3 acceptance assessment. Thus, the analysis population is 35 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 3	94 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 4

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 4. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: Out of the 38 participants still enrolled in the study at week 4, 32 participants completed the week 4 adherence assessment. Thus, the analysis population is 32 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 4	94 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 5

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 5. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 31 participants completed the week 5 acceptance assessment. Thus, the analysis population is 31 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 5	90 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 6

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 6. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 31 participants completed the week 6 acceptance assessment. Thus, the analysis population is 31 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 6	97 Percentage of participants

Primary

Percentage of Participants Reporting Acceptance of Furosemide at Week 8

Participants' acceptance of furosemide will be assessed using an investigator-developed 1-question questionnaire administered at study week 8. Patient-reported acceptance of furosemide at the dose during which the questionnaire is administered will be defined as an affirmative response (yes) to the question If recommended, would you be willing to stay on the dose of furosemide you have received during the last week?. The percentage of participants reporting acceptance of furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 31 participants completed the week 8 acceptance assessment. Thus, the analysis population is 31 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Acceptance of Furosemide at Week 8	90 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 1	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 12	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 14	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious hearing change will be defined as hearing change ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe hearing change attributable to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 1	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 12	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 14	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious rash will be defined as rash ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting a severe or very severe rash attributable to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 1	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 12	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 14	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious chest pain will be defined as chest pain ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe chest pain will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 1	10 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 10	17 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 12	12 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 14	9 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 16	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 18	9 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 2	16 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 3	11 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 4	11 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 5	17 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 6	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious cramping will be defined as cramping ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe cramping attributable to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 8	8 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 1	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 12	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 14	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious diarrhea will be defined as diarrhea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe diarrhea will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Diarrhea Attributable to Furosemide at Week 8	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 1	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 12	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 14	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 2	5 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 4	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 5	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious dizziness/pre-syncope will be defined as dizziness/pre-syncope ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe dizziness/pre-syncope attributable to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Dizziness/Pre-syncope Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 1	5 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 12	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 14	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 3	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 4	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 5	8 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious nausea will be defined as nausea ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe nausea will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Nausea Attributable to Furosemide at Week 8	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 1	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 12	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 14	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 16	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 18	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 3	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 4	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 5	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 6	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious tinnitus will be defined as tinnitus ranked as severe or very severe and attributable to furosemide. Incidence will be defined as percentage of participants who have serious tinnitus. The percentage of participants reporting severe or very severe tinnitus attributable to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Tinnitus Attributable to Furosemide at Week 8	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 1	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 12	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 14	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 16	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 18	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the prior week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious unusual tiredness/weakness will be defined as unusual tiredness/weakness ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe unusual tiredness/weakness will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Unusual Tiredness/Weakness Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 1

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 1. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 1	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 10

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 10. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 36 participants completed the week 10 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 10	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 12

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 12. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 34 participants completed the week 12 symptom questionnaire. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 12	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 14

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 14. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 33 participants completed the week 14 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 14	6 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 16

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 16. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 33 participants completed the week 16 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 16	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 18

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 18. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 33 participants completed the week 18 symptom questionnaire. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 18	3 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 2

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 2. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 2	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 3

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 3. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 symptom questionnaire. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 3	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 4

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 4. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 38 participants completed the week 4 symptom questionnaire. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 4	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 5

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 5. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 5	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 6

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 6. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 6	0 Percentage of participants

Primary

Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 8

Participants' dialysis-related symptoms during the last week will be assessed using an investigator-developed 13-question symptom questionnaire administered at study week 8. Each symptom will be graded using a 5-point symptom severity Likert scale (response options: none, mild, moderate, severe, very severe). Serious vomiting will be defined as vomiting ranked as severe or very severe and attributable to furosemide. The percentage of participants reporting severe or very severe vomiting will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 36 participants completed the week 8 symptom questionnaire. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Reporting Severe or Very Severe Vomiting Attributable to Furosemide at Week 8	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 1

Participants' blood pressure will be measured with an upper extremity cuff in a seated position at 15-minute intervals during each hemodialysis treatment per standard dialysis clinic protocols. Dialysis-associated hypotension will be defined as hypotension during dialysis requiring hospitalization or treatment in an emergency room and not attributable to overt sepsis, acute myocardial infarction, or other cardiovascular event (e.g. aortic dissection). The percentage of participants who have dialysis-associated hypotension up to week 1 will be determined.

Time frame: Up to study week 1 (1 week after study medication start)

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 1	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 10

Time frame: Up to study week 10 (10 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 10. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 10	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 11

Time frame: Up to study week 11 (11 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 11. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 11	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 12

Time frame: Up to study week 12 (12 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 12. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 12	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 13

Time frame: Up to study week 13 (13 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 13. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 13	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 14

Time frame: Up to study week 14 (14 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 14. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 14	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 15

Time frame: Up to study week 15 (15 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 15. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 15	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 16

Time frame: Up to study week 16 (16 weeks after study medication start)

Population: 34 participants were still enrolled in the study at week 16. Thus, the analysis population is 34 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 16	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 17

Time frame: Up to study week 17 (17 weeks after study medication start)

Population: 33 participants were still enrolled in the study at week 17. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 17	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 18

Time frame: Up to study week 18 (18 weeks after study medication start)

Population: 33 participants were still enrolled in the study at week 18. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 18	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 2

Time frame: Up to study week 2 (2 weeks after study medication start)

Population: 38 participants were still enrolled in the study at week 2. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 2	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 3

Time frame: Up to study week 3 (3 weeks after study medication start)

Population: 38 participants were still enrolled in the study at week 3. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 3	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 4

Time frame: Up to study week 4 (4 weeks after study medication start)

Population: 38 participants were still enrolled in the study at week 4. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 4	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 5

Time frame: Up to study week 5 (5 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 5. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 5	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 6

Time frame: Up to study week 6 (6 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 6. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 6	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 7

Time frame: Up to study week 7 (7 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 7. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 7	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 8

Time frame: Up to study week 8 (8 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 8. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 8	0 Percentage of participants

Primary

Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 9

Time frame: Up to study week 9 (9 weeks after study medication start)

Population: 36 participants were still enrolled in the study at week 9. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants That Experience Dialysis-associated Hypotension up to Week 9	0 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 1

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 1. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 36 participants completed the week 1 pill counts. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 1	67 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 10

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 10. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 10 (10 weeks after study medication start)

Population: 24 participants completed the week 10 pill counts. Thus, the analysis population is 24 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 10	75 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 12

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 12. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 12 (12 weeks after study medication start)

Population: 24 participants completed the week 12 pill counts. Thus, the analysis population is 24 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 12	83 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 14

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 14. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 14 (14 weeks after study medication start)

Population: 25 participants completed the week 14 pill counts. Thus, the analysis population is 25 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 14	84 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 16

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 16. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 16 (16 weeks after study medication start)

Population: 25 participants completed the week 16 pill counts. Thus, the analysis population is 25 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 16	48 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 18

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 18. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 18 (18 weeks after study medication start)

Population: 24 participants completed the week 18 pill counts. Thus, the analysis population is 24 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 18	75 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 19

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 19. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 19 (19 weeks after study medication start)

Population: 23 participants completed the week 19 pill counts. Thus, the analysis population is 23 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 19	70 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 2

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 2. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: Out of the 38 participants still enrolled in the study at week 2, 32 participants completed the week 2 pill counts. Thus, the analysis population is 32 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 2	81 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 3

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 3. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 21 participants completed the week 3 pill counts. Thus, the analysis population is 21 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 3	52 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 4

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 4. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 30 participants completed the week 4 pill counts. Thus, the analysis population is 30 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 4	67 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 5

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 5. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 27 participants completed the week 5 pill counts. Thus, the analysis population is 27 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 5	81 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 6

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 6. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 26 participants completed the week 6 pill counts. Thus, the analysis population is 26 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 6	81 Percentage of participants

Primary

Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 8

Participants' adherence to furosemide will be assessed at scheduled pill counts conducted by the study team at study week 8. Participants' adherence to furosemide will be defined \<20% pills remaining at the scheduled pill counts. The percentage of participants who are adherent to furosemide will be determined.

Time frame: Study week 8 (8 weeks after study medication start)

Population: 24 participants completed the week 8 pill counts. Thus, the analysis population is 24 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Are Adherent to Furosemide (<20% Pills Remaining at Scheduled Pill Counts) at Week 8	67 Percentage of participants

Primary

Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 12

Participants will follow standard dialysis clinic protocols for 24-urine volume collection. Classifying participants as has having an increase in 24-hour urine volume will be contingent on the amount of urine the participant makes at baseline. * Among participants with baseline 24-hour urine volume ≥200 mL: ≥25% increase in urine volume is considered an increase. * Among participants with baseline 24-hour urine volume \<200 mL: ≥50 mL increase in urine volume to a urine volume of at least 100 mL/24-hours is considered an increase. The percentage of participants who have a defined increase in 24-urine volume from baseline to week 12 will be determined.

Time frame: Baseline and study week 12 (12 weeks after study medication start)

Population: Summarizing outcome events as a single arm (i.e., patients with a baseline 24-hour urine volume ≥200 mL and \< 200 mL as a single group) was pre-specified in the protocol. 33 participants completed the week 12 24-hour urine volume collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 12	33 Percentage of participants

Primary

Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 18

Time frame: Baseline and study week 18 (18 weeks after study medication start)

Population: Summarizing outcome events as a single arm (i.e., patients with a baseline 24-hour urine volume ≥200 mL and \< 200 mL as a single group) was pre-specified in the protocol. Out of the 33 participants still enrolled in the study at week 18, 32 completed the week 18 24-hour urine volume collection. Thus, the analysis population is 32 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 18	22 Percentage of participants

Primary

Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 5

Time frame: Baseline and study week 5 (5 weeks after study medication start

Population: Summarizing outcome events as a single arm (i.e., patients with a baseline 24-hour urine volume ≥200 mL and \< 200 mL as a single group) was pre-specified in the protocol. 36 participants completed the week 5 24-hour urine volume collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 5	33 percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 10

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 10. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 10 (10 weeks after study medication start)

Population: 36 participants completed the Inner EAR questionnaire at week 10. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 10	0 Percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 14

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 14. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 14 (14 weeks after study medication start)

Population: 33 participants completed the Inner EAR questionnaire at week 14. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 14	3 Percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 18

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 18. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 18 (18 weeks after study medication start)

Population: 33 participants completed the Inner EAR questionnaire at week 18. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 18	6 Percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 2

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 2. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 2 (2 weeks after study medication start)

Population: 37 participants completed the Inner EAR questionnaire at week 2. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 2	0 Percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 4

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 4. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 4 (4 weeks after study medication start)

Population: 38 participants completed the Inner EAR questionnaire at week 4. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 4	3 Percentage of participants

Primary

Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 6

Participants' hearing ability during the last week will be assessed using the Inner Effectiveness of Auditory Rehabilitation (Inner EAR) 11-question validated questionnaire administered during study week 6. The total instrument score will be tallied at each administration \[range: 10 (low hearing ability) - 59 (high hearing ability)\]. Serious hearing change will be defined as a ≥10-point decrease in the Inner EAR instrument score from baseline score. The percentage of participants with a defined decrease in the Inner EAR instrument score will be determined.

Time frame: Baseline and study week 6 (6 weeks after study medication start)

Population: 36 participants completed the Inner EAR questionnaire at week 6. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Defined Decrease in the Inner EAR Instrument Score From Baseline to Week 6	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 1

Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 38 participants completed the week 1 blood collection. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 1	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 13

Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 13 (13 weeks after study medication start)

Population: 33 participants completed the week 13 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 13	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 17

Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 17 (17 weeks after study medication start)

Population: 33 participants completed the week 17 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 17	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 2

Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 2	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 3

Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 3	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 4

Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 37 participants completed the week 4 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 4	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 5

Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 5	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 6

Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 6	0 Percentage of participants

Primary

Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 9

Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum corrected calcium \<7.0 mg/dL will be determined.

Time frame: Study week 9 (9 weeks after study medication start)

Population: 36 participants completed the week 9 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Corrected Calcium <7.0 mg/dL at Week 9	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 1.

Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 38 participants completed the week 1 blood collection. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 1.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 13.

Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 13 (13 weeks after study medication start)

Population: 33 participants completed the week 13 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 13.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 17.

Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 17 (17 weeks after study medication start)

Population: 33 participants completed the week 17 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 17.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 2.

Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 2.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 3.

Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 3.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 4.

Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 37 participants completed the week 4 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 4.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 5.

Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 5.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 6.

Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 6.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 9.

Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum furosemide level \>12 micrograms/L will be determined.

Time frame: Study week 9 (9 weeks after study medication start)

Population: 36 participants completed the week 9 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Furosemide Level >12 Micrograms/L at Week 9.	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 1

Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 38 participants completed the week 1 blood collection. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 1	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 13

Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 13 (13 weeks after study medication start)

Population: 33 participants completed the week 13 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 13	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 17

Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 17 (17 weeks after study medication start)

Population: 33 participants completed the week 17 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 17	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 2

Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 2	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 3

Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 blood collection. However, there was laboratory error and serum magnesium levels were only available for 36 participants. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 3	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 4

Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 37 participants completed the week 4 blood collection. However, there was laboratory error and serum magnesium levels were only available for 36 participants. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 4	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 5

Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 5	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 6

Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 6	0 Percentage of participants

Primary

Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 9

Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum magnesium \<0.8 mEq/L will be determined.

Time frame: Study week 9 (9 weeks after study medication start)

Population: 36 participants completed the week 9 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Magnesium <0.8 mEq/L at Week 9	0 Percentage of participants

Primary

Percentage of Participants With A Serum Potassium <3.2 mEq/L at Week 1

Blood samples will be collected from participants prior to their dialysis treatments at the week 1 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 1 (1 week after study medication start)

Population: 38 participants completed the week 1 blood collection. Thus, the analysis population is 38 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With A Serum Potassium <3.2 mEq/L at Week 1	0 percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 13

Blood samples will be collected from participants prior to their dialysis treatments at the week 13 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 13 (13 weeks after study medication start)

Population: 33 participants completed the week 13 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 13	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 17

Blood samples will be collected from participants prior to their dialysis treatments at the week 17 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 17 (17 weeks after study medication start)

Population: 33 participants completed the week 17 blood collection. Thus, the analysis population is 33 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 17	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 2

Blood samples will be collected from participants prior to their dialysis treatments at the week 2 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 2 (2 weeks after study medication start)

Population: 37 participants completed the week 2 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 2	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 3

Blood samples will be collected from participants prior to their dialysis treatments at the week 3 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 3 (3 weeks after study medication start)

Population: 37 participants completed the week 3 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 3	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 4

Blood samples will be collected from participants prior to their dialysis treatments at the week 4 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 4 (4 weeks after study medication start)

Population: 37 participants completed the week 4 blood collection. Thus, the analysis population is 37 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 4	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 5

Blood samples will be collected from participants prior to their dialysis treatments at the week 5 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 5 (5 weeks after study medication start)

Population: 36 participants completed the week 5 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 5	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 6

Blood samples will be collected from participants prior to their dialysis treatments at the week 6 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 6 (6 weeks after study medication start)

Population: 36 participants completed the week 6 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 6	0 Percentage of participants

Primary

Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 9

Blood samples will be collected from participants prior to their dialysis treatments at the week 9 study visit. The percentage of participants who have a serum potassium \<3.2 mEq/L will be determined.

Time frame: Study week 9 (9 weeks after study medication start)

Population: 36 participants completed the week 9 blood collection. Thus, the analysis population is 36 participants.

Arm	Measure	Value (NUMBER)
Study Drug Administration: Furosemide	Percentage of Participants With a Serum Potassium <3.2 mEq/L at Week 9	0 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Countries

Participant flow

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Change in the Inner EAR Instrument Score From Baseline to Week 1

Change in the Inner EAR Instrument Score From Baseline to Week 12

Change in the Inner EAR Instrument Score From Baseline to Week 16

Change in the Inner EAR Instrument Score From Baseline to Week 3

Change in the Inner EAR Instrument Score From Baseline to Week 5

Change in the Inner EAR Instrument Score From Baseline to Week 8

Percentage of Participants Reporting Acceptance of Furosemide at Week 1

Percentage of Participants Reporting Acceptance of Furosemide at Week 10

Percentage of Participants Reporting Acceptance of Furosemide at Week 12

Percentage of Participants Reporting Acceptance of Furosemide at Week 14

Percentage of Participants Reporting Acceptance of Furosemide at Week 16

Percentage of Participants Reporting Acceptance of Furosemide at Week 18

Percentage of Participants Reporting Acceptance of Furosemide at Week 2

Percentage of Participants Reporting Acceptance of Furosemide at Week 3

Percentage of Participants Reporting Acceptance of Furosemide at Week 4

Percentage of Participants Reporting Acceptance of Furosemide at Week 5

Percentage of Participants Reporting Acceptance of Furosemide at Week 6

Percentage of Participants Reporting Acceptance of Furosemide at Week 8

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 1

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 10

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 12

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 14

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 16

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 18

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 2

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 3

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 4

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 5

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 6

Percentage of Participants Reporting a Severe or Very Severe Hearing Change Attributable to Furosemide at Week 8

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 1

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 10

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 12

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 14

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 16

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 18

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 2

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 3

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 4

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 5

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 6

Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 8

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 1

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 10

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 12

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 14

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 16

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 18

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 2

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 3

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 4

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 5

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 6

Percentage of Participants Reporting Severe or Very Severe Chest Pain Attributable to Furosemide at Week 8

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 1

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 10

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 12

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 14

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 16

Percentage of Participants Reporting Severe or Very Severe Cramping Attributable to Furosemide at Week 18